Industry leader Ian Mattioli joins Kanabo’s investment round and Board, accelerating digital healthcare expansion and treatment portfolio
LONDON–(BUSINESS WIRE)–Kanabo Group (LSE: KNB), a health-tech company focused on patient care with its innovative digital healthcare platform and medical cannabis treatment portfolio, announces Ian Mattioli’s appointment as Chair of the Board. Mattioli’s financial services and capital markets expertise will advance Kanabo’s strategic objectives.
The £2.5M minimum investment round includes an institutional investor, company management, and Ian Mattioli’s £500K investment. This funding will support Kanabo’s UK market expansion, further developing its telehealth offering, and accelerating the integration of additional treatments into its digital health platform and medical cannabis product line.
Ian Mattioli’s Background:
– Co-founder and CEO of Mattioli Woods PLC, a leading UK pensions and wealth management consultancy
– London Stock Exchange AIM Entrepreneur of the Year and CEO of the Year in the City of London Wealth Management Awards in 2018
David Tsur, Kanabo’s outgoing Chair, welcomed Mattioli to the leadership team, stating:
“We are pleased to have Ian Mattioli join us at this pivotal time for Kanabo. His appointment will substantially boost our expansion plans in the digital healthcare sector. Ian’s experience and understanding of London’s capital markets will be invaluable as we work to advance our strategic goals. Since our admission to the London Stock Exchange, we have achieved several significant milestones, including experiencing considerable revenue growth, launching two medical cannabis products, building a comprehensive supply chain, acquiring The GP Service, and launching Treat-It, our innovative digital health platform for pain management.”
Ian Mattioli Kanabo Group’s appointed Chair:
“I am honoured to join Kanabo at this pivotal moment in the company’s journey. As they aim to become a leader in the digital healthcare sector, Kanabo is well-positioned to address the growing need for accessible and specialised medications. The unique end-to-end healthcare solution enables patients to take control of their personalised care and improve their overall health. I see great potential in Kanabo’s innovative approach, the significant market opportunity in the digital health arena, and the rising demand for medicinal cannabis products, setting the foundation for solid growth and success in the coming years.”
More on Kanabo Group:
Kanabo Group Plc (LSE:KNB) is a health-tech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.
Kanabo’s NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.
In March 2023, Kanabo successfully launched its pain clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.
Contacts
Kanabo Group plc
Vigo Consulting (Financial Public Relations/Investor Relations)
Jeremy Garcia / Fiona Hetherington / Verity Snow
+44 (0)20 7390 0230
[email protected]
